Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03076021 · ClinicalTrials.gov registry record · Phase 4
Effects of Isotretinoin on CYP2D6 Activity
A Phase 4 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT03076021 is a Phase 4 study that has completed, run by University of Washington. The registered enrollment target is 33 participants.
The verdict
NCT03076021, a Phase 4 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
Specific Aim: To investigate if isotretinoin (13-cis-retinoic acid) administration decreases CYP2D6 activity in adolescent patients.
Interventions
- DRUG Isotretinoin
- DRUG dextromethorphan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-07-26 |
| Est. Completion | 2023-11-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03076021
The ClinicalTrials.gov registry entry for NCT03076021 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Isotretinoin is the first listed.
NCT03076021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03076021 about?
NCT03076021 is a clinical study titled "Effects of Isotretinoin on CYP2D6 Activity". Specific Aim: To investigate if isotretinoin (13-cis-retinoic acid) administration decreases CYP2D6 activity in adolescent patients.
What is the current status of trial NCT03076021?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2016-07-26. Estimated completion is 2023-11-27.
What interventions are being tested in trial NCT03076021?
The interventions under investigation include: Isotretinoin (DRUG), dextromethorphan (DRUG).
Who is sponsoring clinical trial NCT03076021?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.